Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCB | P05771 | 2/20 | 0.47 |
| ▸ | BCL2 | P10415 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | FADS1 | O60427 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 3/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ABL2 | P42684 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29801540 | 1.00 | PRKCB (0.47) | PRKCBBCL2MEN1KMT2ANPC1 | |
| SCHEMBL4140358 | 0.92 | SENP7 (0.40) | PRKCBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL4140360 | 0.92 | SENP7 (0.40) | PRKCBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL21074342 | 0.88 | SENP8 (0.52) | PRKCBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL29801391 | 0.88 | SENP8 (0.52) | PRKCBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL29801683 | 0.88 | SENP7 (0.44) | PRKCBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL19859149 | 0.88 | SENP7 (0.44) | PRKCBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL21048266 | 0.88 | MIF (0.42) | PRKCBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL21074378 | 0.88 | STING1 (0.43) | PRKCBMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL21048265 | 0.88 | MIF (0.42) | PRKCBMEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000839-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS ON BASIS OF AMPK INHIBITORY FUNCTION AND ZINC HOMEOSTASIS CONTROL FUNCTION | ZINCURE CORP. (KR) | 2023-01-05 | — | — | US | claimed |
| EP-4066832-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS ON BASIS OF AMPK INHIBITORY FUNCTION AND ZINC HOMEOSTASIS CONTROL FUNCTION | Zincure Corp. (KR) | 2022-10-05 | — | — | EP | claimed |
| WO-2021096270-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS ON BASIS OF AMPK INHIBITORY FUNCTION AND ZINC HOMEOSTASIS CONTROL FUNCTION | 주식회사 진큐어 | 2021-05-20 | — | — | WO | claimed |
| US-12343335-B2 | Pharmaceutical composition for treating multiple sclerosis on basis of AMPK inhibitory function and zinc homeostasis control function | ZINCURE CORP. (KR) | 2025-07-01 | — | — | US | disclosed |
| US-20230000839-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS ON BASIS OF AMPK INHIBITORY FUNCTION AND ZINC HOMEOSTASIS CONTROL FUNCTION | ZINCURE CORP. (KR) | 2023-01-05 | — | — | US | disclosed |
| US-20230000839-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS ON BASIS OF AMPK INHIBITORY FUNCTION AND ZINC HOMEOSTASIS CONTROL FUNCTION | ZINCURE CORP. (KR) | 2023-01-05 | — | — | US | disclosed |
| EP-4066832-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS ON BASIS OF AMPK INHIBITORY FUNCTION AND ZINC HOMEOSTASIS CONTROL FUNCTION | Zincure Corp. (KR) | 2022-10-05 | — | — | EP | disclosed |
| EP-3498277-B1 | PHARMACEUTICAL COMPOSITION FOR STROKE TREATMENT BASED ON AMPK INHIBITION | ZINCURE CORP (KR) | 2021-10-06 | — | — | EP | disclosed |
| WO-2021096270-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS ON BASIS OF AMPK INHIBITORY FUNCTION AND ZINC HOMEOSTASIS CONTROL FUNCTION | 주식회사 진큐어 | 2021-05-20 | — | — | WO | disclosed |
| EP-3498277-A1 | PHARMACEUTICAL COMPOSITION FOR STROKE TREATMENT BASED ON AMPK INHIBITION | Industry Academy Cooperation Foundation Of Sejong University (KR) | 2019-06-19 | — | — | EP | disclosed |
| US-20190167647-A1 | PHARMACEUTICAL COMPOSITION FOR STROKE TREATMENT BASED ON AMPK INHIBITION | ZINCURE CORP. (KR) | 2019-06-06 | — | — | US | disclosed |
| WO-2018030762-A1 | PHARMACEUTICAL COMPOSITION FOR STROKE TREATMENT BASED ON AMPK INHIBITION | 세종대학교산학협력단 | 2018-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000839-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS ON BASIS OF AMPK INHIBITORY FUNCTION AND ZINC HOMEOSTASIS CONTROL FUNCTION | PRKAB1, PRKAB2, PRKAG1 | PRKCB 7/4885BCL2 487/4885MEN1 3953/4885 |
| US-20190167647-A1 | PHARMACEUTICAL COMPOSITION FOR STROKE TREATMENT BASED ON AMPK INHIBITION | PRKAG1, PRKAB1, PRKAG2 | PRKCB 10/4885BCL2 2404/4885MEN1 3192/4885 |
| US-12343335-B2 | Pharmaceutical composition for treating multiple sclerosis on basis of AMPK inhibitory function and zinc homeostasis control function | PRKAB1, PRKAB2, PRKAG1 | PRKCB 7/4885BCL2 487/4885MEN1 3953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.